Search

Your search keyword '"Ortved Gang, Anne"' showing total 15 results
Start Over Author "Ortved Gang, Anne"
15 results on '"Ortved Gang, Anne"'

1. Deep immune cell phenotyping and induced immune cell responses at admission stratified by BMI in patients hospitalized with COVID-19: An observational multicenter cohort pilot study

Author

Sejdic, Adin, Hartling, Hans Jakob, Gitz Holler, Jon, Klingen Gjærde, Lars, Matovu Dungu, Arnold, Engel Møller, Maria Elizabeth, Svanberg Teglgaard, Rebecca, Utoft Niemann, Carsten Utoft, Brooks, Patrick Terrence, Mogensen, Trine H., Weis, Nina, Podlekareva, Daria, Baum Jørgensen, Marie Louise, Ortved Gang, Anne, Stampe Hersby, Ditte, Hald, Annemette, Dam Nielsen, Susanne, Lebech, Anne-Mette, Helleberg, Marie, Lundgren, Jens, Træholt Franck, Kristina, Fischer, Thea K., Barrella Harboe, Zitta, Marquart, Hanne Vibeke, Rye Ostrowski, Sisse, and Lindegaard, Birgitte

Published
2024
Full Text
View/download PDF

2. Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma.

Author

Jelicic, Jelena, Juul‐Jensen, Karen, Bukumiric, Zoran, Runason Simonsen, Mikkel, Roost Clausen, Michael, Ludvigsen Al‐Mashhadi, Ahmed, Schou Pedersen, Robert, Bjørn Poulsen, Christian, Ortved Gang, Anne, Brown, Peter, El‐Galaly, Tarec Christoffer, and Larsen, Thomas Stauffer

Subjects
PROGNOSIS, DIFFUSE large B-cell lymphomas, DISEASE risk factors, OVERALL survival, PROGNOSTIC models
Abstract

Background: Several clinical prognostic models for diffuse large B‐cell lymphoma (DLBCL) have been proposed, including the most commonly used International Prognostic Index (IPI), the National Comprehensive Cancer Network IPI (NCCN‐IPI), and models incorporating beta‐2 microglobulin (β2M). However, the role of β2M in DLBCL patients is not fully understood. Methods: We identified 6075 patients with newly diagnosed DLBCL treated with immunochemotherapy registered in the Danish Lymphoma Registry. Results: A total of 3232 patients had data available to calculate risk scores from each of the nine considered risk models for DLBCL, including a model developed from our population. Three of four models with β2M and NCCN‐IPI performed better than the International Prognostic Indexes (IPI, age‐adjusted IPI, and revised IPI). Five‐year overall survival for high‐ and low‐risk patients were 43.6% and 86.4% for IPI and 34.9% and 96.2% for NCCN‐IPI. In univariate analysis, higher levels of β2M were associated with inferior survival, higher tumor burden (advanced clinical stage and bulky disease), previous malignancy and increased age, and creatinine levels. Furthermore, we developed a model (β2M‐NCCN‐IPI) by adding β2M to NCCN‐IPI (c‐index 0.708) with improved discriminatory ability compared to NCCN‐IPI (c‐index 0.698, p < 0.05) and 5‐year OS of 33.1%, 56.2%, 82.4%, and 96.4% in the high, high‐intermediate, low‐intermediate and low‐risk group, respectively. Conclusion: International Prognostic Indices, except for NCCN‐IPI, fail to accurately discriminate risk groups in the rituximab era. β2M, a readily available marker, could improve the discriminatory performance of NCCN‐IPI and should be re‐evaluated in the development setting of future models for DLBCL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Outcome of limited‐stage peripheral T‐Cell lymphoma after CHOP (−like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group

Author

Ludvigsen Al‐Mashhadi, Ahmed, primary, Cederleuf, Henrik, additional, Kuhr Jensen, Rasmus, additional, Holm Nielsen, Torsten, additional, Bjerregård Pedersen, Martin, additional, Bech Mortensen, Thomas, additional, Relander, Thomas, additional, Jerkeman, Mats, additional, Ortved Gang, Anne, additional, Kristensen, Anne Louise, additional, Roost Clausen, Michael, additional, de Nully Brown, Peter, additional, Tang Severinsen, Marianne, additional, Jakobsen, Lasse Hjort, additional, Ellin, Fredrik, additional, and El‐Galaly, Tarec Christoffer, additional

Published
2023
Full Text
View/download PDF

6. Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site

Author

Chapman-Fredricks, Jennifer R, primary, Thakkar, Devang, additional, Alderuccio, Juan Pablo, additional, Naresh, Kikkeri N, additional, Ondrejka, Sarah L., additional, Hsi, Eric D., additional, Xu, Mina L, additional, Paulson, Nathan, additional, Koff, Jean L., additional, Jaye, David L, additional, Cohen, Jonathon B., additional, Ortved Gang, Anne, additional, Leeman-Neill, Rebecca J, additional, Dave, Tushar, additional, Happ, Lanie, additional, Love, Cassandra, additional, Zandi, Sasan, additional, Naushad, Hina, additional, Mason, Emily F, additional, Louissaint, Abner, additional, Martin, Haley, additional, Ong, Choon Kiat, additional, Pillai, Raju, additional, Pedersen, Mette Ø, additional, Yin, C. Cameron, additional, Choi, William, additional, Au-Yeung, Rex Kwok Him, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Chadburn, Amy, additional, Sarno, Vincent, additional, McKinney, Matthew, additional, Sojitra, Payal, additional, Evans, Andrew G, additional, Behdad, Amir, additional, Galvez, Carlos, additional, Cheng, Chee Leong, additional, Czader, Magdalena, additional, Yan, Jiong, additional, Dave, Sandeep S., additional, and Lossos, Izidore S., additional

Published
2022
Full Text
View/download PDF

7. Outcome after 3rd Line Treatment for Diffuse Large B-Cell Lymphoma: A Danish Population-Based Study

Author

Ludvigsen Al-Mashhadi, Ahmed, primary, Jakobsen, Lasse Hjort, additional, Brown, Peter de Nully, additional, Ortved Gang, Anne, additional, Thorsteinsson, Anne-Luise, additional, Rasoul, Kaziwa, additional, Melchior Heissmann, Judith, additional, Buch Tøstesen, Michael, additional, Nieman Christoffersen, Mette, additional, Jelicic, Jelena, additional, Bøgh Jørgensen, Jennifer, additional, Thomsen, Troels, additional, Dessau-Arp, Andriette, additional, Andersen, Andreas PH, additional, Frederiksen, Mikael, additional, Pedersen, Per Troellund, additional, Clausen, Michael Roost, additional, Jørgensen, Judit, additional, Poulsen, Christian Bjørn, additional, El-Galaly, Tarec Christoffer Christoffer, additional, and Larsen, Thomas S., additional

Published
2022
Full Text
View/download PDF

8. P115: Distinct signaling pathways and checkpoint molecule expression across histological subtypes of nodular lymphocyte-predominant Hodgkin lymphoma

Author

Kalashnikov, Ilja, primary, Kositsky, Rachel, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Dunkel, Johannes, additional, Pasanen, Annika, additional, Love, Cassandra, additional, Parker, Clay, additional, Ondrejka, Sarah, additional, Hsi, Eric, additional, Juskevicius, Ridas, additional, Evans, Andrew, additional, Evans, Andrew G., additional, Czader, Magdalena, additional, Wang, Lin, additional, Xu, Mina, additional, Paulson, Nathan, additional, Pedersen, Mette ølgod, additional, Ortved Gang, Anne, additional, Koff, Jean, additional, Mccal, Chad, additional, Natkunam, Yaso, additional, Louissaint, Abner, additional, Shin Yeu, Ong, additional, Pillai, Raju, additional, Chapman, Jennifer, additional, Amador, Catalina, additional, Chadburn, Amy, additional, Goswami, Rashmi, additional, Behdad, Amir, additional, Sojitra, Payal, additional, Tse, Eric, additional, Kikkeri, Naresh, additional, Nasresh, Kikkeri N., additional, Fedoriw, Yuri, additional, Dave, Sandeep, additional, and Leppä, Sirpa, additional

Published
2022
Full Text
View/download PDF

9. Outcome of limited‐stage peripheral T‐Cell lymphoma after CHOP(−like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.

Author

Ludvigsen Al‐Mashhadi, Ahmed, Cederleuf, Henrik, Kuhr Jensen, Rasmus, Holm Nielsen, Torsten, Bjerregård Pedersen, Martin, Bech Mortensen, Thomas, Relander, Thomas, Jerkeman, Mats, Ortved Gang, Anne, Kristensen, Anne Louise, Roost Clausen, Michael, de Nully Brown, Peter, Tang Severinsen, Marianne, Jakobsen, Lasse Hjort, Ellin, Fredrik, and El‐Galaly, Tarec Christoffer

Published
2023
Full Text
View/download PDF

10. Risk of Incident Diabetes and Dysregulated Pre-Existing Diabetes Mellitus in Newly Diagnosed Lymphoma Patients Treated with Steroid-Containing Immunochemotherapy: A Danish Population-Based Study

Author

Baech, Joachim, primary, Severinsen, Marianne Tang, additional, Øvlisen, Andreas Kiesbye, additional, Frederiksen, Henrik, additional, Vestergaard, Peter, additional, Torp-Pedersen, Christian, additional, Jørgensen, Judit M., additional, Clausen, Michael Roost, additional, Poulsen, Christian Bjørn, additional, Brown, Peter de Nully, additional, Ortved Gang, Anne, additional, Pedersen, Robert Schou, additional, Ekstroem Smedby, Karin, additional, Eloranta, Sandra, additional, Jakobsen, Lasse H., additional, and El-Galaly, Tarec Christoffer, additional

Published
2021
Full Text
View/download PDF

11. Therapeutic Cancer Vaccination Targeting Shared Tumor Associated Antigens in Combination with Azacitidine for High Risk Myelodysplastic Syndrome - a Phase I Clinical Trial

Author

Holmberg-Thydén, Staffan, primary, Dufva, Inge Høgh, additional, Ortved Gang, Anne, additional, Fredslund Breinholt, Marie, additional, Schejbel, Lone, additional, Andersen, Mette Klarskov, additional, Kadivar, Mohammad, additional, Svane, Inge Marie, additional, Grønbæk, Kirsten, additional, Reker Hadrup, Sine, additional, and El Fassi, Daniel, additional

Published
2020
Full Text
View/download PDF

12. Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups

Author

Zhang, Jenny, primary, Reddy, Anupama, additional, Love, Cassandra, additional, Moffitt, Andrea B., additional, Rajagopalan, Deepthi, additional, Leppä, Sirpa, additional, Pasanen, Annika, additional, Meriranta, Leo, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Norgaard, Peter H, additional, Pederson, Mette, additional, Ortved Gang, Anne, additional, Hogdall, Estrid, additional, Richards, Kristy L., additional, Fedoriw, Yuri D., additional, Bernal-Mizrachi, Leon, additional, Koff, Jean L., additional, Staton, Ashley D., additional, Flowers, Christopher, additional, Paltiel-Clarfield, Ora, additional, Goldschmidt, Neta, additional, Calaminici, Maria, additional, Clear, Andrew James, additional, Gribben, John, additional, Nguyen, Evelyn, additional, Czader, Magdalena, additional, Ondrejka, Sarah Lynn, additional, Collie, Angela, additional, Hsi, Eric D, additional, au-Yeung, Rex, additional, Yok-Lam, Kwong, additional, Choi, Wai Lap, additional, Srivastava, Gopesh, additional, Evens, Andrew M, additional, Pilichowska, Monika, additional, Sengar, Manju, additional, Reddy, Nishitha, additional, Li, Shaoying, additional, Jaffe, Elaine S., additional, Tzeng, Tiffany, additional, Datta, Jyotishka, additional, Dunson, David, additional, and Dave, Sandeep, additional

Published
2016
Full Text
View/download PDF

13. Outcome after 3rdLine Treatment for Diffuse Large B-Cell Lymphoma: A Danish Population-Based Study

Author

Ludvigsen Al-Mashhadi, Ahmed, Jakobsen, Lasse Hjort, Brown, Peter de Nully, Ortved Gang, Anne, Thorsteinsson, Anne-Luise, Rasoul, Kaziwa, Melchior Heissmann, Judith, Buch Tøstesen, Michael, Nieman Christoffersen, Mette, Jelicic, Jelena, Bøgh Jørgensen, Jennifer, Thomsen, Troels, Dessau-Arp, Andriette, Andersen, Andreas PH, Frederiksen, Mikael, Pedersen, Per Troellund, Clausen, Michael Roost, Jørgensen, Judit, Poulsen, Christian Bjørn, El-Galaly, Tarec Christoffer Christoffer, and Larsen, Thomas S.

Published
2022
Full Text
View/download PDF

14. A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients.

Author

Jelicic, Jelena, Juul‐Jensen, Karen, Bukumiric, Zoran, Runason Simonsen, Mikkel, Roost Clausen, Michael, Ludvigsen Al‐Mashhadi, Ahmed, Schou Pedersen, Robert, Bjørn Poulsen, Christian, Ortved Gang, Anne, Brown, Peter, El‐Galaly, Tarec Christoffer, and Stauffer Larsen, Thomas

Abstract

ABSTRACT Objectives Methods Results Conclusion Recent front‐line clinical trials used the International Prognostic Index (IPI) to identify trial‐eligible patients with newly diagnosed diffuse large B‐cell lymphoma (DLBCL). However, many IPI‐like variants with improved accuracy have been developed over the years for rituximab‐treated patients.We assessed the impact of International Prognostic Indices on patient enrolment in clinical trials, aiming to exclude low‐risk IPI patients based on POLARIX/EPCORE DLBCL‐2 trial criteria.We identified 2877 patients in the Danish Lymphoma Registry who would have been eligible for the POLARIX trial if patients with IPI 0–1 scores were included. IPI and NCCN‐IPI assigned 33.3% and 11.9% of patients to the low‐risk group, respectively. Shorter 5‐year overall survival (91.4% vs. 97.5%), higher relapse rate (9.9% vs. 4.4%), and more deaths (16.1% vs. 4.4%) occurred in the low‐risk IPI group compared with low‐risk NCCN‐IPI group. Analyzed models failed to identify true high‐risk patients with poor prognosis. Similar results were found in the confirmatory cohort developed based on EPCORE DLBCL‐2 trial eligibility criteria.True low‐risk patients are more optimal identified by NCCN‐IPI and should be excluded from front‐line clinical trials due to their excellent prognosis. However, additional high‐risk factors besides clinical prognostic models need to be considered when selecting trial‐eligible patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.

Author

Ludvigsen Al-Mashhadi A, Cederleuf H, Kuhr Jensen R, Holm Nielsen T, Bjerregård Pedersen M, Bech Mortensen T, Relander T, Jerkeman M, Ortved Gang A, Kristensen AL, Roost Clausen M, de Nully Brown P, Tang Severinsen M, Jakobsen LH, Ellin F, and El-Galaly TC

Subjects
Adult, Humans, Middle Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Treatment Outcome, Stem Cell Transplantation, Doxorubicin, Prednisone adverse effects, Vincristine, Cyclophosphamide, Lymphoma, T-Cell, Peripheral drug therapy, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large-Cell, Anaplastic
Abstract

Peripheral T-Cell Lymphomas (PTCLs) are rare, aggressive lymphomas with poor outcomes, but limited-stage disease is infrequent and not well-described. This study reports outcomes and prognostic factors in limited-stage nodal PTCLs in a binational population-based setting. Patients were identified from the Danish and Swedish lymphoma registries. Adults diagnosed with limited-stage nodal PTCL (stage I-II) and treated with CHOP(-like) therapy ±radiotherapy between 2000 and 2014 were included. Medical records were reviewed by local investigators. A total of 239 patients with a median age of 62 years were included; 67% received 6-8 cycles of CHOP(-like) therapy and 22% received 3-4 cycles, of which 59% also received radiotherapy. Autologous stem cell transplant consolidation was administered to 16% of all patients. Median follow-up was 127 months with 5-years overall survival (OS) of 58% (95% CI: 53-65) and progression-free survival (PFS) of 53% (95% CI: 47-59). In multivariable analysis, age ≥ 60 years and B-symptoms were unfavorable and ALK+ anaplastic large cell T-Cell lymphoma was favorable for survival outcomes. There was no difference in treatment-specific outcome (3-4 cycles vs. 6-8 cycles of CHOP(-like) ± radiotherapy). Low-risk patients (age < 60 without B-symptoms) had a 5-year OS of 77% (95% CI 67-89%). In the present study of limited-stage nodal PTCL, survival after curative intent chemotherapy +/- radiotherapy was inferior to that of limited-stage diffuse large B-cell lymphoma, but a subgroup of young patients without B-symptoms had very good outcomes. Treatment outcomes after 3-4 cycles versus 6-8 cycles of CHOP(-like) therapy were comparable., (© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results